FDA clears Paragonix’s pediatric donor heart transport system

The SherpaPak is designed to maintain a safe temperature evenly across the donor organ, indicated for up to 4 hours of use. (Image: Paragonix)

The FDA has cleared a new insulated organ transport system designed for shepherding small and pediatric hearts from donors to transplant recipients.

The latest version of Paragonix Technologies’ SherpaPak Cardiac Transport System includes connectors covering most aorta sizes, allowing both adult and pediatric hearts to be carried in its proprietary suspension system.

The company said the upgraded product will begin shipping in the first quarter of 2019. The single-use SherpaPak system is the only FDA cleared and CE marked system for donor heart transport and storage.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

It’s designed to maintain a safe preservation temperature evenly across the donor organ, between 4 and 8 degrees Celsius, compared to the traditional use of uncontrolled ice chests and coolers.

While the storage temperature has been validated for more than 12 hours in various environments, according to Paragonix, its FDA 510(k) clearance is indicated for up to four hours of use. The device is currently marketed in the U.S., United Kingdom, France, Spain, Italy, Germany, Austria and Slovakia.

“Our goal is to establish a new standard of care for donor organ preservation and with our FDA-cleared and CE-marked devices for both heart and kidney organ stage and transport, we are on our way to making this a reality,” said Bill Edelman, Paragonix’s chairman and CEO.

The company’s donor lung transport system and active heart preservation system, providing oxygenated perfusion, are not yet available in the U.S.

Suggested Articles

Bio-Rad Laboratories received FDA clearance for two digital PCR products designed to monitor CML patients’ molecular responses to treatment.

Neuspera Medical raised a total of $26 million through the second tranche of a series B round, to fund clinical testing programs for its implants.

Voyager stands to receive up to $728 million in milestones for each compound AbbVie chooses to advance beyond phase 1.